Trial NCT00698685

View at ClinicalTrials.gov 
Aliases: NCT00543283
Org. Study IDs: 05-0624-04
Secondary IDs: 05110 R21CA106177 UARIZ-05-0624-01 UARIZ-SRC17920

Last trial update was posted on 2017-03-31

MeSH Interventions

Alemtuzumab Pentostatin

MeSH Conditions

Carcinoma, Renal Cell Hematologic Neoplasms Hodgkin Disease Leukemia Multiple Myeloma

Other Conditions

Hodgkin's Disease Lymphoma

Stopping Reasons

Pentostatin/alemtuzumab regimen had greater risk of graft failure.

Limitations And Caveats

We did not meet criteria to stop the study because of nonrelapse mortality (safety endpoint). However, we stopped accrual to the study because of failure to meet minimal criteria for engraftment (efficacy endpoint).

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID